Table 2 General characteristic of T2DM and control group for validation study
Clinical characteristics | T2DM (n = 100) | control (n = 90) | P value |
|---|---|---|---|
Sex (male/female) | 45/55 | 43/47 | 0.701 |
Age (years) | 49.2 ± 12.2 | 46.5 ± 10.4 | 0.302 |
BMI (kg/m2) | 24.2 (22.9–25.9) | 20.8 (20.1–24.5) | 0.047 |
DBP (mmHg) | 78 (70–80) | 73 (68–80) | 0.124 |
SBP (mmHg) | 138 (130–140) | 130 (125–140) | 0.003 |
WBC (× 109/L) | 4.8 (4.4–5.7) | 4.7 (4.5–5.8) | 0.984 |
FPG (mmol/L) | 10.7 (8.8–13.2) | 5.3 (4.9–5.8) | 0.000 |
HbA1c (%) | 9.3 (8.0–11.5) | 4.8 (4.4–5.1) | 0.000 |
FINS (uIu/ml) | 5.3 (3.7–8.3) | 7.2 (6.7–8.7) | 0.000 |
HOMA-B | 11.7(6.5–24) | 108.8(91.6–141.9) | < 0.001 |
HOMA-IR | 2.5(1.6–4.1) | 1.6(1.4–2.0) | < 0.001 |
TG (mmol/l) | 1.7 (1.0–2.3) | 1.2 (0.9–1.8) | 0.278 |
LDL-C (mmol/l) | 2.8 ± 0.8 | 2.5 ± 0.5 | 0.002 |
HDL-C (mmol/l) | 1.1 ± 0.3 | 1.3 ± 0.3 | 0.000 |
UA (mmol/L) | 336.1 ± 59.5 | 330.5 ± 79.5 | 0.576 |